GlassScriptPhysician profile
Stacey Berrios
NPI 1578744264
$4,144.93
in general payments reported to CMS, 2019-2025
26 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $874 · 2023: $801 · 2024: $834 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.73 |
| Education | $219.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $740.36 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $510.89 | 2021-2023 | Cresemba, Xospata |
| Sanofi-Aventis U.S. LLC | $404.87 | 2024-2025 | |
| Kite Pharma, INC. | $372.52 | 2022-2024 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $288.36 | 2022-2025 | Calquence, Lynparza |
| Beigene USA, INC. | $275.36 | 2021-2025 | Brukinsa |
| Beone Medicines USA, INC. | $175.48 | 2025 | Brukinsa, Tevimbra |
| Adaptive Biotechnologies Corporation | $169.07 | 2022-2024 | Clonoseq |
| Incyte Corporation | $152.37 | 2021-2024 | Jakafi |
| Pharmaessentia USA Corporation | $143.79 | 2024 | Besremi |
| Csl Behring | $123.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.02 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $122.97 | 2023 | Imbruvica |
| Genzyme Corporation | $101.89 | 2025 | |
| Pfizer INC. | $93.06 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $58.93 | 2025 | Datroway, Enhertu |
| Adc Therapeutics America, INC. | $45.94 | 2024 | |
| Sobi, INC | $42.95 | 2024 | |
| Tela Bio, INC. | $42.66 | 2022 | |
| Glaxosmithkline, LLC. | $30.00 | 2024 | Ojjaara |
| Celgene Corporation | $28.33 | 2024 | Reblozyl |
| Blueprint Medicines Corporation | $22.63 | 2025 | Ayvakit |
| Genentech USA, INC. | $21.06 | 2024 | Columvi, Polivy, Lunsumio |
| Genmab U.S., INC. | $20.02 | 2023 | Epkinly |
| Novartis Pharmaceuticals Corporation | $17.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.48 | 2023 | Ninlaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Berrios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.